Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1244472.RAfLWbP2oIPrJgi2_SGr9iCHIpwofe7I4Qd2eku-2xFaI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1244472.RAfLWbP2oIPrJgi2_SGr9iCHIpwofe7I4Qd2eku-2xFaI130_assertion type Assertion NP1244472.RAfLWbP2oIPrJgi2_SGr9iCHIpwofe7I4Qd2eku-2xFaI130_head.
- NP1244472.RAfLWbP2oIPrJgi2_SGr9iCHIpwofe7I4Qd2eku-2xFaI130_assertion description "[Several approaches have been explored in the past few years including: monoclonal antibodies - either 'naked' (rituximab) or in combination with an immunotoxin (calicheamicin or maytansin), plant toxin (ricin), or bacterial toxin (Pseudomonas or diphtheria), and a novel bispecific T-cell-engaging antibody (blinatumomab); chimeric antigen therapy using autologous T cells that target CD19-expressing ALL; and novel agents such as proteasome inhibitors, liposomal vincristine, hypomethylating agents, nelarabine and NOTCH1 inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244472.RAfLWbP2oIPrJgi2_SGr9iCHIpwofe7I4Qd2eku-2xFaI130_provenance.
- NP1244472.RAfLWbP2oIPrJgi2_SGr9iCHIpwofe7I4Qd2eku-2xFaI130_assertion evidence source_evidence_literature NP1244472.RAfLWbP2oIPrJgi2_SGr9iCHIpwofe7I4Qd2eku-2xFaI130_provenance.
- NP1244472.RAfLWbP2oIPrJgi2_SGr9iCHIpwofe7I4Qd2eku-2xFaI130_assertion SIO_000772 25471034 NP1244472.RAfLWbP2oIPrJgi2_SGr9iCHIpwofe7I4Qd2eku-2xFaI130_provenance.
- NP1244472.RAfLWbP2oIPrJgi2_SGr9iCHIpwofe7I4Qd2eku-2xFaI130_assertion wasDerivedFrom befree-2016 NP1244472.RAfLWbP2oIPrJgi2_SGr9iCHIpwofe7I4Qd2eku-2xFaI130_provenance.
- NP1244472.RAfLWbP2oIPrJgi2_SGr9iCHIpwofe7I4Qd2eku-2xFaI130_assertion wasGeneratedBy ECO_0000203 NP1244472.RAfLWbP2oIPrJgi2_SGr9iCHIpwofe7I4Qd2eku-2xFaI130_provenance.